WO1999006061A1 - Prediction, detection, and design of t cell epitopes - Google Patents
Prediction, detection, and design of t cell epitopes Download PDFInfo
- Publication number
- WO1999006061A1 WO1999006061A1 PCT/US1998/015563 US9815563W WO9906061A1 WO 1999006061 A1 WO1999006061 A1 WO 1999006061A1 US 9815563 W US9815563 W US 9815563W WO 9906061 A1 WO9906061 A1 WO 9906061A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- average
- antigen
- polypeptide segment
- unstable
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title abstract description 10
- 238000013461 design Methods 0.000 title description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 216
- 239000000427 antigen Substances 0.000 claims abstract description 170
- 108091007433 antigens Proteins 0.000 claims abstract description 168
- 102000036639 antigens Human genes 0.000 claims abstract description 168
- 238000000034 method Methods 0.000 claims abstract description 122
- 229960005486 vaccine Drugs 0.000 claims abstract description 25
- 230000028993 immune response Effects 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 240
- 108090000623 proteins and genes Proteins 0.000 claims description 228
- 102000004169 proteins and genes Human genes 0.000 claims description 220
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 212
- 229920001184 polypeptide Polymers 0.000 claims description 163
- 150000001408 amides Chemical class 0.000 claims description 73
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- 241001465754 Metazoa Species 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 25
- 208000023275 Autoimmune disease Diseases 0.000 claims description 22
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 22
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 22
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 21
- 244000052769 pathogen Species 0.000 claims description 21
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 20
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 20
- 239000004473 Threonine Substances 0.000 claims description 20
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 20
- 229960000310 isoleucine Drugs 0.000 claims description 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 20
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 20
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 20
- 239000004474 valine Substances 0.000 claims description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 17
- 229930182817 methionine Natural products 0.000 claims description 17
- 230000001717 pathogenic effect Effects 0.000 claims description 17
- 230000002163 immunogen Effects 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 239000004365 Protease Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 239000013566 allergen Substances 0.000 claims description 7
- 210000005170 neoplastic cell Anatomy 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 201000010099 disease Diseases 0.000 abstract description 8
- 230000001976 improved effect Effects 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 150
- 210000004027 cell Anatomy 0.000 description 74
- 241000725303 Human immunodeficiency virus Species 0.000 description 52
- 230000004044 response Effects 0.000 description 42
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 238000012545 processing Methods 0.000 description 28
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 24
- 108010014251 Muramidase Proteins 0.000 description 20
- 102000016943 Muramidase Human genes 0.000 description 20
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 20
- 230000030741 antigen processing and presentation Effects 0.000 description 20
- 230000003053 immunization Effects 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 238000003780 insertion Methods 0.000 description 20
- 230000037431 insertion Effects 0.000 description 20
- 229960000274 lysozyme Drugs 0.000 description 20
- 239000004325 lysozyme Substances 0.000 description 20
- 235000010335 lysozyme Nutrition 0.000 description 20
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 19
- 239000012071 phase Substances 0.000 description 18
- 230000002797 proteolythic effect Effects 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 210000002443 helper t lymphocyte Anatomy 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 101710192063 Gene 31 protein Proteins 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 12
- 241000282560 Macaca mulatta Species 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 230000005867 T cell response Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 241000282553 Macaca Species 0.000 description 9
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108010022394 Threonine synthase Proteins 0.000 description 8
- 102000004419 dihydrofolate reductase Human genes 0.000 description 8
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102000004266 Collagen Type IV Human genes 0.000 description 7
- 108010042086 Collagen Type IV Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 241000186362 Mycobacterium leprae Species 0.000 description 7
- 241000288906 Primates Species 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 229940028885 interleukin-4 Drugs 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 108010059013 Chaperonin 10 Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010021083 hen egg lysozyme Proteins 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 238000002169 hydrotherapy Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000008072 Lymphokines Human genes 0.000 description 5
- 108010074338 Lymphokines Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940064914 retrovir Drugs 0.000 description 5
- 230000003614 tolerogenic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100030497 Cytochrome c Human genes 0.000 description 4
- 108010075031 Cytochromes c Proteins 0.000 description 4
- 208000024869 Goodpasture syndrome Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 4
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000036436 anti-hiv Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000004940 costimulation Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000006337 proteolytic cleavage Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 3
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 3
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 3
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 101000599943 Macaca mulatta Interferon gamma Proteins 0.000 description 3
- 101001033230 Macaca mulatta Interleukin-10 Proteins 0.000 description 3
- 101001043755 Macaca mulatta Interleukin-2 Proteins 0.000 description 3
- 101001002706 Macaca mulatta Interleukin-4 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000012510 peptide mapping method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101100484673 Enterobacteria phage T4 31 gene Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001074285 Liparis <scorpaeniform fish> Species 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010071811 Simian immunodeficiency virus Gag protein p27 Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 2
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000003977 lipoyl group Chemical group S1SC(C([H])([H])C(C(C(C(=O)[*])([H])[H])([H])[H])([H])[H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000191851 Macacine gammaherpesvirus 4 Species 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- IJGRMHOSHXDMSA-ZDOIIHCHSA-N Nitrogen-15N2 Chemical compound [15N]#[15N] IJGRMHOSHXDMSA-ZDOIIHCHSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000027223 regulation of cytokine secretion Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 108010076805 snowdrop lectin Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- Antigen-specific immunity is mediated by lymphocytes, a specialized group of white blood cells.
- the two types of lymphocytes, B and T are capable of recognizing and binding to an antigen.
- B lymphocytes typically recognize and bind to an entire antigen (i.e., a long polypeptide chain that has both secondary and tertiary structural elements).
- T lymphocytes bind to a peptide that is derived from the entire antigen in a mechanism termed antigen processing. T lymphocytes will only recognize the peptide when it is presented in context with major histocompatibility complex (MHC) proteins expressed on the surface of another cell.
- MHC major histocompatibility complex
- MHC major histocompatibility
- Germain and Margulies Ann. Rev. Immunol. 11 : 403-450, 1993; Germain, G., Cell 76: 287-299, 1994.
- Mechanisms of antigen processing and presentation limit the spectrum of peptides that can be recognized by T-cell receptors. Nevertheless, for a given antigen sequence, many more peptides should satisfy the requirements of MHC binding than actually are observed in the population of naturally processed and presented peptides. The peptides actually observed are called the immunodominant epitopes of the antigen. The ability to selectively predict and generate immunodominant epitopes would improve vaccine development and therapies for immunological diseases.
- the invention features a method for stimulating an immune response specific toward a naturally-occurring protein in an animal having an immune system that includes T cells, where the method includes administering to the animal an altered protein derived from the naturally-occurring protein, wherein an unstable polypeptide segment has been inserted by artifice into the altered protein.
- the naturally occurring-protein is from a pathogen, and the altered protein is administered to the animal to prevent infection of the animal with the pathogen.
- the naturally occurring-protein is from a neoplastic cell, and the altered protein is administered to the animal to inhibit growth of the neoplastic cell in the animal.
- the altered protein is administered with a pharmaceutically acceptable carrier, an adjuvant, or both.
- the animal is a mammal (e.g., a human).
- the invention provides a method for increasing the immunogenicity of a naturally-occurring protein by inserting by artifice into the naturally-occurring protein an unstable polypeptide segment to produce an altered protein.
- the naturally-occurring protein is from a pathogen or a neoplastic cell.
- the altered protein, or polypeptide fragment thereof is in a vaccine.
- the unstable polypeptide segment includes at least twelve amino acid residues.
- not more than 30% of the amino acid residues of the unstable polypeptide segment are isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, or methionine.
- the unstable polypeptide segment includes a polypeptide sequence that is specifically recognized by a protease.
- the unstable polypeptide segment has an average hydrophobicity value that is lower than the average hydrophobicity value of the altered protein; has a sequence conservation that is lower than a sequence conservation of the altered protein; has an amide protection factor that is lower than 10 4 wherein the altered protein is in a native conformational state; has an average amide protection factor that is lower than the average amide protection factor for the altered protein in a denatured conformational state; has an NMR order parameter (S 2 ) of less than 0.8, and preferably less than 0.7; or has an average B-factor value that is higher than the average B-factor value of the altered protein.
- S 2 NMR order parameter
- the altered protein includes a T cell epitope.
- the unstable polypeptide segment is inserted N-terminally adjacent to the T cell epitope.
- the C - terminal portion of the unstable polypeptide segment overlaps the N - terminal portion of the T cell epitope.
- the T cell epitope has an average hydrophobicity value that is higher than the average hydrophobicity value of the altered protein; has a sequence conservation that is higher than a sequence conservation of the altered protein; has an amide protection factor that is greater than 10 4 wherein the altered protein is in a native conformational state; has an average amide protection factor that is higher than the average amide protection factor for the altered protein in a denatured conformational state; has an NMR order parameter (S 2 ) of greater than 0.7; or has an average B-factor value that is lower than the average B-factor value of the altered protein.
- At least 30% of the amino acid residues of the T cell epitope are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine.
- the invention features a method for detecting in a substantially pure protein a polypeptide segment that is likely to be a T-cell epitope includes first, identifying an unstable polypeptide segment in the protein; and, second, identifying a second polypeptide segment adjacent to the unstable polypeptide segment, the second polypeptide segment likely to be a T cell epitope.
- the unstable polypeptide segment includes at least twelve amino acid residues. In another embodiment, not more than 30% of the amino acid residues of the unstable polypeptide segment are isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, or methionine. In another embodiment, the unstable polypeptide segment includes a polypeptide sequence that is specifically recognized by a protease.
- the unstable polypeptide segment has an average hydrophobicity value that is lower than the average hydrophobicity value of the substantially pure protein; has a sequence conservation that is lower than a sequence conservation of the substantially pure protein; has an amide protection factor that is lower than 10 4 wherein the substantially pure protein is in a native conformational state; has an average amide protection factor that is lower than the average amide protection factor for the substantially pure protein in a denatured conformational state; has an NMR order parameter (S 2 ) of less than 0.8; or has an average B-factor value that is higher than the average B-factor value of the substantially pure protein.
- the unstable polypeptide segment is N-terminally adjacent to the second polypeptide segment.
- the C - terminal portion of the unstable polypeptide segment overlaps the N - terminal portion of the second polypeptide segment.
- the second polypeptide segment has an average hydrophobicity value that is higher than the average hydrophobicity value of the protein; has a sequence conservation that is higher than a sequence conservation of the protein; has an amide protection factor that is greater than 10 4 wherein the protein is in a native conformational state; has an average amide protection factor that is higher than the average amide protection factor for the protein in a denatured conformational state; has an NMR order parameter (S 2 ) of greater than 0.7, and preferably greater than 0.8; or has an average B-factor value that is lower than the average B-factor value of the protein.
- At least 30% of the amino acid residues of the second polypeptide segment are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine.
- the invention features a method for identifying the most immunogenic protein in a group of proteins, the method including identifying the protein including the most unstable polypeptide segment in the group of proteins, wherein the identified protein is the most immunogenic protein in the group of proteins.
- the most immunogenic protein is substantially purified and the group of proteins is from a neoplastic cell, a pathogen, a foodstuff, an allergen, or a tissue targeted in an autoimmune disease.
- the most unstable polypeptide segment includes at least twelve amino acid residues. In another embodiment, not more than 30% of the amino acid residues of the most unstable polypeptide segment are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine.
- the most unstable polypeptide segment has the lowest average hydrophobicity value of any unstable polypeptide segment of the group of proteins; has the lowest sequence conservation of any unstable polypeptide segment of the group of proteins; has the lowest average amide protection factor of any unstable polypeptide segment of the group of proteins wherein the proteins in the group are in a native conformational state; has the lowest average amide protection factor of any unstable polypeptide segment of the proteins wherein the proteins in the group are in a denatured conformational state; has the lowest NMR order parameter (S 2 ) of any unstable polypeptide segment of the group of proteins; or has the average highest B-factor value of any unstable polypeptide segment of the group of proteins.
- the most immunogenic protein includes a T cell epitope.
- the most unstable polypeptide segment is N-terminally adjacent to the T cell epitope.
- the C - terminal portion of the most unstable polypeptide segment overlaps the N - terminal portion of the T cell epitope.
- the T cell epitope has an average hydrophobicity value that is higher than the average hydrophobicity value of the protein; has a sequence conservation that is higher than a sequence conservation of the protein; has an amide protection factor that is greater than 10 4 wherein the protein is in a native conformational state; has an average amide protection factor that is higher than the average amide protection factor for the protein in a denatured conformational state; has an NMR order parameter (S 2 ) of greater than 0.7; or has an average B-factor value that is lower than the average B- factor value of the protein.
- At least 30% of the amino acid residues of the T cell epitope are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine.
- the invention features a method for treating an animal that has or is at risk for developing an allergic response, the method including administering to the animal a protein or polypeptide fragment thereof from an allergen, wherein said protein or polypeptide fragment thereof is identified as comprising the most unstable polypeptide segment in a group of proteins of said allergen.
- the invention features a method for treating an animal that has or is at risk for developing an autoimmune disease, the method including administering to the animal a protein or polypeptide fragment thereof from a tissue targeted in said immune disease wherein said protein or polypeptide fragment thereof is identified as comprising the most unstable polypeptide segment in a group of proteins of said tissue targeted in said autoimmune disease.
- the protein or polypeptide fragment thereof is in a tolerogen. In another embodiment, the protein or polypeptide fragment thereof is administered orally, or is administered with a pharmaceutically acceptable carrier. In other embodiments, the animal is a mammal (e.g., a human).
- the invention features a substantially pure antigen that includes an unstable polypeptide segment that has been inserted by artifice.
- the antigen is associated with a pharmaceutically acceptable carrier, an adjuvant, or both.
- the unstable polypeptide segment includes at least twelve amino acid residues. In another embodiment, not more than 30% of the amino acid residues of the unstable polypeptide segment are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine. In another embodiment, the unstable polypeptide segment includes a polypeptide sequence that is specifically recognized by a protease.
- the unstable polypeptide segment has an average hydrophobicity value that is lower than the average hydrophobicity value of the substantially pure antigen; has a sequence conservation that is lower than a sequence conservation of the substantially pure antigen; has an amide protection factor that is lower than 10 4 wherein the substantially pure antigen is in a native conformational state; has an average amide protection factor that is lower than the average amide protection factor for the substantially pure antigen in a denatured conformational state; has an NMR order parameter (S 2 ) of less than 0.8, and preferably less than 0.7; or has an average B-factor value that is higher than the average B-factor value of the substantially pure antigen.
- S 2 NMR order parameter
- the substantially pure antigen includes a T cell epitope.
- the unstable polypeptide segment is inserted N-terminally adjacent to the T cell epitope.
- the C - terminal portion of the unstable polypeptide segment overlaps the N - terminal portion of the T cell epitope.
- the T cell epitope has an average hydrophobicity value that is higher than the average hydrophobicity value of the antigen; has a sequence conservation that is higher than a sequence conservation of the antigen; has an amide protection factor that is greater than 10 4 wherein the antigen is in a native conformational state; has an average amide protection factor that is higher than the average amide protection factor for the antigen in a denatured conformational state; has an NMR order parameter (S 2 ) of greater than 0.7; or has an average B-factor value that is lower than the average B-factor value of the antigen.
- At least 30%) of the amino acid residues of the T cell epitope are selected from the group of amino acid residues consisting of isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, and methionine.
- the invention features a vaccine that includes the antigen of the seventh aspect of the invention.
- the invention features a tolerogen that includes the antigen of the seventh aspect of the invention.
- the invention features a method for determining the capacity of an animal to mount an antigen-specific T lymphocyte response that includes first, administering to the animal an antigen identified as having at least one unstable polypeptide segment, second, providing the antigen, or a polypeptide fragment thereof, to a T lymphocyte isolated from the animal, and, third, measuring the response of the T lympchoyte, where a response indicates that the animal is capable of an antigen-specific T lymphocyte response to the antigen.
- the invention features a method for detecting an autoimmune disease, or a predisposition to develop an autoimmune disease, in an animal that includes first, providing an antigen from the animal, or a polypeptide fragment thereof, to a T lymphocyte isolated from the animal, and, second, measuring the response of the T lympchoyte, where a response indicates the animal has or is predisposed to develop an autoimmune disease.
- a mammal may be a goat, rabbit, pig, horse, donkey, elephant, camel, sheep, guinea pig, rat, mouse, chimpanzee, gorilla, gibbon, llama, macaque, or marine mammal.
- Animals of the invention may be warm-blooded mammals and non-mammals (e.g., birds), as well as cold-blooded vertebrates and invertebrates.
- Pathogens of the invention include, without limitation, viruses (e.g., the human immunodeficiency virus), bacteria, protozoans, helminths, and yeasts.
- the invention features a method for using engineered T cell epitopes to stimulate either TH1 or TH2 helper T lymphocyte responses.
- the invention features a method for using engineered T cell epitopes to tolerize a patient to an antigen having the T cell epitope by selectively removing epitope-reactive T cells from the patient's blood.
- the invention features a method for using engineered T cell epitopes to tolerize a patient to an antigen having the T cell epitope by selectively rendering epitope-reactive T cells in the patient's blood anergic by stimulating the T cells with the epitope plus autologous MHC in the absence of co-stimulatory molecules.
- antigen-presenting cell a cell that expresses MHC protein on its cell surface.
- a preferable antigen-presenting cell expresses MHC class II proteins on its cell surface, and a most preferable antigen-presenting cell expresses both MHC class I and MHC class II proteins on its cell surface.
- epitope or T cell epitope is meant a polypeptide, or a fragment thereof, derived from or corresponding to an antigen that is expressed on the surface of an antigen-presenting cell in context with MHC class I or MHC class II proteins.
- the cell-bound complex of epitope plus MHC is specifically recognized by the T cell receptor on the cell surface of a T lymphocyte.
- a T cell epitope is generally a stable polypeptide fragment, with at least 30% of its amino acid residues being isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, or methionine residues, more preferably, at least 40%, still more preferably, at least 50% and most preferably, at least 70% of its amino acid residues being isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, or methionine residues.
- An T cell epitope may be defined by a high NMR order parameter (S 2 ).
- a high NMR order parameter is an NMR order parameter which is greater than 0.7, and, more preferably, greater than 0.8.
- high NMR order parameter is meant the high degree of order exhibited by NMR-active nuclei on the time scale of picoseconds to nanoseconds as determined by NMR relaxation processes.
- T cell epitope may be defined as having a higher than average hydrophobicity (as determined by a Kyte-Doolittle scale) relative to the hydrophobicity of the entire polypeptide. More preferably, a T cell epitope may be defined by the presence of high sequence conservation.
- sequence conservation is meant a large number of residues are identical in the same molecule expressed in different species (e.g., a hemoglobin molecule from a monkey versus a hemoglobin molecule from a human). Sequence identity is typically measured using sequence analysis software with the default parameters specified therein (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705).
- a T cell epitope may be defined by having a lower B- factor value relative to the B-factor values of the entire polypeptide.
- low B- factors is meant a lower than average disorder or higher than average strong diffraction of X-rays (as determined by X-ray crystallography).
- high amide protection is meant an amide protection factor that is higher than 10 4 in a native protein or higher than the average amide protection factor for all residues in a denatured protein.
- amide protection factor is meant the rate of hydrogen exchange with solvent deuterons of the amide in an unstructured model peptide divided by the rate of hydrogen exchange for the amide in the context of the protein.
- stable polypeptide segment is meant a chain of amino acids which shows increased flexibility compared to the entire polypeptide, of which the chain of amino acids is a segment.
- An unstable polypeptide segment is preferentially subject to proteolytic cleavage during antigen processing, and is preferably at least twelve amino acid residues in length.
- no more than 30% of the amino acids of an unstable polypeptide segment are hydrophobic amino acids (i.e., preferably not more than 30% of the residues are isoleucine, leucine, valine, tyrosine, phenylalanine, tryptophan, threonine, or methionine residues.
- An unstable polypeptide segment may be defined by a low NMR order parameter (S 2 ).
- a low NMR order parameter is an NMR order parameter which is less than 0.8, and is preferably lower than 0.7.
- low NMR order parameter is meant the low degree of order exhibited by NMR- active nuclei on the time scale of picoseconds to nanoseconds as determined by NMR relaxation processes.
- an unstable polypeptide segment may be defined as having a lower than average hydrophobicity (as dete ⁇ ined by a Kyte-Doolittle scale) relative to the average hydrophobicity of the entire polypeptide. More preferably, an unstable polypeptide segment may be defined by the presence of low sequence conservation.
- low sequence conservation is meant a low number of residues are identical in the same molecule expressed in different species (e.g., a hemoglobin molecule from a monkey versus a hemoglobin molecule from a human). Sequence identity is typically measured as described above. Even more preferably, an unstable polypeptide segment may be defined by having high average B-factor value relative to the average B-factor value of the entire polypeptide. By “high B-factors” is meant a higher than average disorder or lower than average strong diffraction of X-rays (as determined by X-ray crystallography). Most preferably, an unstable polypeptide segment may be defined by having low amide protection. By “low amide protection” is meant an average amide protection factor that is lower than 10 4 in a native protein or lower than the average amide protection factor for all residues in a denatured protein.
- antigen is meant a protein or polypeptide that may be derived from any source.
- adjuvant is meant a substance which, when given with an antigen, enhances the immune response to that antigen.
- inserted by artifice is meant a protein or polypeptide that has been manipulated by standard techniques for altering polypeptide sequences or nucleic acids encoding polypeptide sequences (including, without limitation, site specific mutagenesis, deletion, point mutation, homologous recombination, PCR, endonuclease digestion, and ligation), such that the amino acid sequence of the resulting protein has been altered from its naturally-occurring form.
- a protein has been inserted by artifice to include as unstable polypeptide segment. It will be understood that a protein that has been inserted by artifice may not necessarily be greater in length than the naturally occurring protein from which it was derived. For example, a protein may be inserted by artifice, such that a portion of the amino acid sequences of the naturally-occurring protein are deleted or altered.
- protein or “polypeptide” is meant any chain of more than two amino acids, regardless of post-translational modification such as glycosylation or phosphorylation.
- substantially pure polypeptide is meant a polypeptide that has been separated from the components that naturally accompany it.
- the polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.
- the polypeptide is an antigen or a T cell epitope thereof that is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, pure.
- a substantially pure polypeptide may be obtained, for example, by extraction from a natural source (e.g.
- a fibroblast, neuronal cell, or lymphocyte by expression of a recombinant nucleic acid encoding a polypeptide, and engineered antigen polypeptide, or T cell epitope thereof, or by chemically synthesizing the polypeptide.
- Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a polypeptide is substantially free of naturally associated components when it is separated from those contaminants which accompany it in its natural state.
- a polypeptide which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides not only includes those derived from eukaryotic organisms but also those synthesized in E. coli or other prokaryotes.
- pharmaceutically acceptable carrier a carrier which is physiologically acceptable to the treated mammal while retaining the therapeutic properties of the compound with which it is administered.
- One exemplary pharmaceutically acceptable carrier is physiological saline.
- Other physiologically acceptable carriers and their formulations are known to one skilled in the art and described, for example, in Remington's Pharmaceutical Sciences. (18 lh edition), ed. A. Gennaro, 1990, Mack Publishing Company, ⁇ aston, PA.
- pathogen is meant an agent which can cause disease. Exemplary pathogens include viruses (e.g., HIV) and parasites (e.g., helminths, bacteria, and protozoa).
- allergen is meant an antigen that generates an allergic reaction.
- tolerogen is meant an antigen that inhibits an antigen-specific immune response.
- immunogen an antigen that generates an antigen-specific immune response.
- hydrophobic amino acid is meant an amino acid residue which is aversive to water and forms clusters with like residues.
- exemplary hydrophobic amino acids include isoleucine (He), leucine (Leu), valine (Val), tyrosine (Tyr), phenylalanine (Phe), Tryptophan (Tip), threonine (Thr), and methionine (Met).
- TH1 a CD4 + helper T lymphocyte response that results in the activation of CD8 + cytotoxic T lymphocytes.
- TH1 helper T cells produce a number of characteristic cytokines including interleukin-2 (IL-2), interleukin-12 (IL-12), and interferon- ⁇ (IFN- ⁇ ).
- IL-2 interleukin-2
- IL-12 interleukin-12
- IFN- ⁇ interferon- ⁇
- TH2 a CD4' helper T lymphocyte response that results in the activation of antibody-producing B lymphocytes.
- TH2 helper T cells produce a number of characteristic cytokines including interleukin-4 (IL-4) and interleukin-lO (IL-lO).
- IL-4 interleukin-4
- IL-lO interleukin-lO
- Fig. 1 A is a schematic diagram of the amino acid sequence of the HsplO protein, M. leprae cpnlO.
- the T cell epitope at residues 26-42 is shown in solid black (Kim et al, J. Immunol. 159: 335-343, 1997), and the mobile loop at residues 19-35 is shown in speckled black.
- Fig. IB is an X-ray crystal structure of E. coli cpnlO (Hunt et al, Nature 379: 37-45, 1996). Grayscale indicates disorder; low B-factors are in dark gray and high B-factors are in light gray. The mobile loop is indicated.
- Fig. 2A is a schematic diagram of the amino acid sequence of staphylococcal nuclease. T-cell epitopes are shown in black (Finnegan et al, J. Exp. Med. 164: 897- 910, 1986).
- Fig. 2B is a series of three panels charting the positions in staphylococcal nuclease of log (protection factor) (Loh et al, Biochemistry 32: 1 1022-11028, 1993), order parameters (Kay et al, Biochemistry 28: 8972-8979, 1989), and B-factors (A 2 ) for the amide nitrogen atoms (Brookhaven Protein Data Bank: 1STN).
- Fig. 3 A is a schematic diagram of the amino acid sequence of hen egg lysozyme. T-cell epitopes are shown in black (Gammon et al, J. Exp. Med. 173: 609- 617, 1991).
- Fig. 3B is a series of three panels charting the positions in hen egg lysozyme of log (protection factor), order parameters (Buck et al, Biochemistry 34: 4041-4055, 1995), and B-factors (A 2 ) for the amide nitrogen atoms (Brookhaven Protein Data Bank: 2LYM). Hydrogen exchange protection factors were generated from the data in Radford et al. (Prot. Struct. Funct. Genet. 14: 237-248, 1992) by dividing exchange rates observed at pH 7.5 and 30°C by 10 seconds " '.
- Fig. 4 is a series of three schematic diagrams for the amino acid sequences of staphylococcal nuclease, hen egg lysozyme, and cytochrome c, wherein the T-cell epitopes are shown in solid black, and flexible loops are shown in speckled black above the T-cell epitopes.
- Fig. 5A is a graph showing the correlation of lysozyme 's T cell epitopes with unstable segments at various offsets. The maximum negative correlation is achieved at an offset of -6.
- Fig. 5B is a scattergram of lysozyme T cell epitope score versus log
- Fig. 6 is a series of schematic diagrams showing the relationship of immunodominant regions to solvent-exposed, proteolytically sensitive sites in HIV gpl20.
- Fig. 7 is a graph showing the correlation of T-cell epitopes with the change
- Fig. 8 is a graph showing the correlation of T-cell epitopes with adjacent regions having high crystallographic B-factors in lysozyme. The epitopes were defined as in Fig. 7. B-factors for backbone amide nitrogens from the Brookhaven Database (21ym) were averaged with a 5-residue window. Epitopes are in the 15- residue segment from the C-terminal edge of the region of high B-factors. A region of high B-fact ⁇ rs is designated as having higher than the average value (14.4, indicated by the horizontal line) for all sequence positions.
- Fig. 9 is a graph showing the correlation of T-cell epitopes with sequence conservation in lysozyme.
- Epitopes were defined as in Fig. 7. Sequence conservation was evaluated for seventy lysozyme sequences. The most popular residue at each position was determined, and then scored for its use at that position in each sequence. Conservative substitutions were counted the same as identical matches. Conservation scores were averaged with a 9-residue window. Epitopes are located in regions with above average conservation (>0.69). Although the correlation does not appear to be very striking, when the epitope score is correlated with conservation 8 residues toward the N-terminus, the Pearson correlation coefficient is -0.57. Thus, epitopes are correlated with poorly conserved regions (processing sites) 8 residues toward the N- terminus.
- Fig. 10 is a graph showing the correlation of T-cell epitopes with hydropathy in lysozyme. Epitopes were defined as in Fig. 7. Epitopes tended to occur in regions with above average hydropathy values (11 -residue window).
- Fig. 11 A is a graph showing the correlation of T-cell epitopes with sequence conservation in HIV gpl20.
- Epitope identifications were obtained from the HIV Immunology Database (http://hiv-web.lanl.gov), which includes a compilation of epitopes published prior to the year 1995 (see Fig. 1 IB). Sequence positions found in multiple epitopes are scored multiple times. Epitope scores were smoothed by an 1 1- residue averaging window. Sequence conservation was evaluated for twenty-three gpl20 sequences. The most popular residue at each position was determined, and then scored for its use at that position in each sequence. Conservative substitutions were counted the same as identical matches. Conservation scores were averaged with a 11 -residue window. Epitopes are located in regions with above average conservation (>0.87).
- Fig. 11B is the sequence of HIV g ⁇ l20 (SEQ ID NO: 1) obtained from the HIV Immunology Database (http://hiv-web.lanl.gov) showing the 36 epitope identifications of epitopes published prior to the year 1995.
- Fig. 12 is a graph showing the correlation of T-cell epitopes with hydropathy in HIV gpl20. Epitope scores were evaluated as described in Fig. 11. The hydropathy profile was calculated using the Kyte and Doolittle scale with a window size of 11. Little or no correlation was evident.
- Figs. 13 A, 13B, and 13C are graphs showing the combination of predictive methods based on MHC binding and preferred processing at poorly conserved regions.
- Fig. 13 A the raw experimental epitope scores are shown.
- Fig. 13B epitopes were predicted by the EpiMatrix analysis available at http://hiv- web.lanl.gov/immuno/articles/LANL.html (no geographic bias in MHC preferences, 20% match to motifs allowed).
- Fig. 13C the EpiMatrix scores were set to zero when the sequence conservation at that residue fell below the average for the whole protein. Note in particular the elimination of predicted epitopes in the segment 130- 200.
- Fig. 14 is a graph showing the correlation of T-cell epitopes with the combined epitope prediction.
- Experimental epitope scores are as defined in Fig. 7, and predicted epitope scores from Fig. 13C were smoothed by an averaging window of 11 residues.
- Pearson correlation coefficient is below 0.2, visual inspection showed a very good qualitative correlation.
- the poor quantitative correlation may be due to the unsystematic identification of T-cell epitopes.
- Some epitopes may be over-represented in the sample for reasons unrelated to processing or presentation.
- Fig. 15 is a series of schematic diagrams of the amino acid sequence of HIV gpl20 indicating (with arrows) the sites of insertion for an unstable polypeptide segment, the human HsplO mobile loop.
- Figs. 16A-16D depict the immunodominant helper T cell epitopes in bacteriophage T4 Gp31.
- Fig. 16A is a bar graph depicting the Stimulation Index (SI) of 15-mer synthetic peptides derived from Gp31.
- Fig. 16B is a graph showing the hydropathy values of Gp31. Shown below the graphed values is the amino acid sequence of Gp31 (SEQ ID NO: 2).
- Fig. 16C is a schematic of the 15-mer peptides derived from Gp31. The immunodominant peptides (i.e. , the peptides having a SI value greater than 1) are shown in black.
- Fig. 16D is a graph showing the B-factor values for Gp31.
- T cell epitopes are peptides generated by the processing of antigens that are presented by MHC proteins to T cells.
- the spectrum of immunogenic epitopes from a given antigen is limited by the range of peptides generated by processing and by the binding preferences of the MHC proteins.
- many more peptides of a given antigen are predicted to bind to MHC proteins than are actually observed to restimulate T cells that were primed with the naturally processed antigen.
- antigen processing is biased toward production of certain peptides.
- I have determined that preferential proteolytic cleavage in poorly ordered regions of a substrate polypeptide provides a mechanism for biased production of certain peptides.
- Mobility of protein regions may be demonstrated by NMR and protease sensitivity (see, for example, determination for the GroES loop in Landry et al, Nature 364: 255-258, 1993).
- PDC mitochondrial pyruvate dehydrogenase complex
- cpnl O Mycobacterium leprae chaperonin 10
- the lipoyl domains of the PDC E2 subunit contain the immunodominant epitopes known to be associated with the autoimmune disease primary biliary cirrhosis.
- the lipoyl domains are sufficiently flexible to be observed by solution-phase nuclear magnetic resonance (NMR) despite the large size of the PDC, and they are preferentially cleaved by proteases (Perham and Duckworth, Nature 292: 474-477, 1981).
- the leprae cpnlO protein an Hspl O protein, contains one immunodominant epitope (Kim et al, J. Immunol. 159: 335-343, 1997) (Fig. IA) which overlaps a mobile loop which were identified in the homologous sequence of the Escherichia coli cpnlO, GroES (Fig. IB). No electron density corresponding to the mobile loop was observed in the M. leprae cpnlO crystal structure, presumably due to disorder, and density was observed for the loop of only one of seven subunits in the crystal structure of E. coli GroES (Hunt et al, Nature 379: 37-45, 1996).
- Crystallographic B-factors (also known as temperature factors) weight the contribution of atoms in the back-calculation of electron density from the model structure. High B-factors correspond to weak density. Information concerning the origin of high B-factors is not directly available from the data. High B-factors can result from time-averaged fluctuations or static inhomogeneity.
- T cells primed with native staphylococcal nuclease gave the strongest proliferative responses to epitopes adjacent to a segment with highly elevated B-factors (Fig. 2A and bottom panel of Fig. 2B).
- B-factors Fig. 2A and bottom panel of Fig. 2B.
- seven determinant cores have been identified, and there is a similar number of peaks in the B-factor profile (Fig. 3 A and bottom panel of Fig. 3B).
- epitopes occurred in well-ordered regions between flexible sites, consistent with a processing mechanism in which proteolytic nicking of the native protein generates fragments that ultimately are presented in the MHC proteins.
- NMR Nuclear magnetic resonance
- the nuclear Overhauser effect refers to the transfer of magnetization between two nuclei, a form of longitudinal (spin-spin) relaxation.
- the magnitude of the NOE is affected by the distance between the nuclei and the rate of molecular motion.
- 'H-'H NOEs are used determine the structure of protein molecules.
- amide b N-'H NOEs are used to measure motion. The distance dependence is not a factor because the 15 N and 'H atoms are bonded to each other and therefore nearly equidistant for all amide groups.
- An order parameter generally describes the correlation of two vectors in space.
- An order parameter derived from protein 15 N-'H relaxation data describes the correlation of a vector along the NH bond with a fixed axis of the molecule.
- a low order parameter indicates motion that is independent of the molecular rotation.
- An S 2 value of unity corresponds to atomic motion that is perfectly correlated with the overall molecular rotation. Typical values for well-ordered regions of a protein are in excess of 0.8.
- T-cell epitopes in staphylococcal nuclease and lysozyme lie adjacent to highly mobile segments.
- Residues 45-49, 69-74 and 1 15-120 in lysozyme exhibit S 2 values below 0.8, and these segments all have high B-factors in the crystal structure (Fig. 2B, middle panel).
- the segment 42-49 in staphylococcal nuclease is highly mobile by NMR (Torchia et al, Structure 28: 5509-5524, 1989), and this is part of a segment with high B-factors. Resonances for this segment were difficult to detect and assign, probably because conformational fluctuations occur close to the NMR time-scale
- HX hydrogen-deuterium exchange
- backbone amide HX protection is analyzed by two-dimensional NMR spectra. Amide proton occupancy is monitored with a series of experiments over time after the protein is dissolved in deuterium oxide. During this period, amide protons exchange for the NMR-inactive deuterons. Generally, amide protons involved in hydrogen bonds exhibit significant HX protection; thus, the signal persists for at least a few minutes, which is the length of time necessary to acquire the first spectrum. The most stable segments of proteins are highly protected against HX, with signals persisting for months.
- the protection factor is the hydrogen-deuterium exchange rate for an amide group in an unstructured peptide divided by the exchange rate of a specific amide group in the protein.
- cytochrome c assignment of stable and unstable segments was as specified on the basis of amide protection factors (Bai et al, Science 269: 192-197, 1995).
- lysozyme T-cell epitopes were determined by proliferation assays using three series of peptides that were 10, 12, and 15 residues in length and spanning the lysozyme sequence in one-residue steps (Gammon et al, J. Exp. Med 173: 609-617, 1991). Maps were determined for BIO.
- A, BALB.B, and BALB/c strains of mice Only epitopes determined for BIO. A and BALB/c strains were considered in this analysis since all epitopes determined for the BALB.B strain overlapped those determined with the BIO. A strain. It is likely that detailed differences between the BIO. A and BALB.B epitopes derive from differences in MHC alleles. For staphylococcal nuclease, the peptide series was composed of 20-mers having 10-residue overlaps (Finnegan et al, J. Exp. Med 164: 897-910, 1986).
- the epitopes overlapped the intervening unstable regions and were displaced to the C-terminal side.
- This pattern was consistent with a mechanism of antigen processing that is initiated via proteolytic cleavage near the center of a locally disordered polypeptide segment, followed by binding of the proximal sequence of the C-terminal product in the MHC class II cleft. Presumably, fine-tuning of the binding site within a particular peptide would occur at the level of MHC recognition. Further proteolytic trimming of the peptide might occur in the context of the peptide-MHC class II complex.
- the number and position of T-cell epitopes correlated with the number and position of unstable segments identified by amide protection factors.
- the apparent correlation between unstable segments and T-cell epitopes is borne out by statistical analysis of the data for lysozyme (Figs. 5 A and 5B) and staphylococcal nuclease. Each residue was assigned a T-cell epitope "score" (1 or 0) on the basis of whether or not it was part of an epitope. Pearson correlation coefficients (r) were calculated for epitope scores and log (protection factors). Correlation coefficients also were calculated after smoothing the data with a moving average using window sizes ranging from 3 to 1 1. Without offsetting the epitope scores, the correlation was near zero for both lysozyme and staphylococcal nuclease.
- T-cell epitopes occur in the regions immediately C-terminal from unstable segments; and within a region, exact sequences of the epitopes can be predicted by the selectivity of MHC alleles.
- the strength of the correlation between flexible sites and epitopes can be assessed by the coefficient of determination (r 2 ).
- helper T-cell epitopes in Human immunodeficiency irus ( ⁇ IV) gpl20 tend to cluster near sites that may be preferentially cleaved during antigen processing (Fig. 6).
- Epitopes were defined using a variety of T-cell stimulation systems, for example, with lymphocytes from draining lymph nodes of mice immunized with native gpl20 (Cease et al, Proc. Natl. Acad. Sci. USA 84: 4249-4253, 1987), peripheral blood lymphocytes from humans immunized with vaccinia virus expressing gpl20
- Epitopes are broadly distributed over the C-terminal half of gp 120. Fewer epitopes occur in the N-terminal half of the protein, although there is a cluster in the region, 101-1 19, including the "T2" epitope (Cease et al, supra). Overlapping epitopes may be grouped into eight regions (shown as gray boxes in Fig.
- immunodominant sequences that encompass most of the gpl20 sequence: 31-54, 64-84, 101-119, 203-269, 273-301, 306-369, 417-453, and 457-502. However, several much shorter segments are over-represented in the sample of reported epitopes.
- immunodominant sequences as those occurring in at least four epitopes: 104-115, 225-236, 294-297, 311-349, 426-440, and 486-500.
- the number of immunodominant regions (shown as black boxes in Fig. 6) is very similar to the number of solvent-exposed segments (shown as white boxes in Fig.
- pathogens might take advantage of bias in the processing mechanism to suppress the development or activation of deleterious T cells.
- T-cell epitope that is preferentially presented in B cells but is consistently bypassed in macrophages.
- This strategy as described herein may be particularly effective for parasites that bear highly repeated, structurally disorganized immunodominant surface antigens.
- My detection of the correlation of instability with T cell epitopes suggests that new T cell epitopes could be introduced, or the immunogenicity of existing epitopes could be enhanced in an antigen, by incorporating unstable segments near the desired target epitopes.
- T-cell epitopes tend to be most abundant on the C-terminal flank of poorly ordered antigen segments. An absence of epitopes within poorly ordered segments is consistent with their preferential proteolysis. The apparent bias toward presentation of the C-terminal product may be due to an inherent preference by the MHC proteins or other intrinsic feature of the presentation mechanism.
- T-cell epitopes (also referred to herein as “epitopes”) can be predicted in the following ways (in order of most effective to least effective): I. Hydrogen-deuterium exchange NMR
- HX protection factor is defined as the rate of exchange of the amide in a disordered model peptide divided by the rate observed in the context of the protein. Regions of low amide protection are preferred processing sites. Epitopes lie in the adjacent sequences.
- HX protection factors are evaluated using the logarithms of the HX protection factors.
- a. Epitopes are located in regions where the average HX protection factor increases over a length of the polypeptide chain, in the amino-terminal to carboxy- terminal direction of the polypeptide.
- the average change of average HX protection factor is evaluated as follows: (i) the HX protection factors are "smoothed" by assigning to each position the average of the HX protection factor for that position and the two flanking positions (a three-residue window); (ii) the change in average value for each position is evaluated by subtracting the value at the previous position; (iii) the change in HX protection is averaged for a window of seven (7) residues.
- Epitopes are found where the average change in HX protection is positive (Fig. 7). The precise location of the epitope is determined by compatibility of the sequence with binding to MHC proteins. b. Epitopes are adjacent to processing sites identified by at least six (6) consecutive residues with HX protection factors below 10 4 for the antigen in its native conformational state. Typically, epitopes are within fifteen (15) residues of the C-terminal edge of the region of low protection. c. Epitopes are located between regions of low HX protection or within regions of high HX protection. High and low HX protection are defined relative to the average protection factor for all amide groups in the protein. This criterion replaces that of lb for amide exchange data obtained for the antigen in a denatured state.
- X-ray crystallographic B-factors are assigned to each atom during the refinement phase of the determination of molecular structures by X-ray crystallography. Poorly ordered atoms diffract x-rays weakly. The B-factor adjusts the contribution of the atom to the electron density map, with a higher B-factor yielding a lower density. Poorly ordered segments have high average B-factors for amide nitrogen atoms. Regions with high B-factors are preferred processing sites. The average B-factor is evaluated with an averaging window with an optimal length of five (5) residues. Epitopes are adjacent to and on the C-terminal side of antigen segments characterized by high average amide nitrogen B-factors (Fig. 8). Typically, epitopes are within fifteen (15) residues of the C-terminal edge of the region of high B-factors. III. Sequence conservation
- Residues that are important for specifying the three-dimensional structure of a protein tend to be conserved as identical among homologs in different species or viral strains.
- the sequence is less constrained where the structure is poorly ordered, and fewer residues are conserved as identical. Therefore, regions of low sequence conservation are preferred processing sites.
- Epitopes are located between regions of low sequence conservation or within regions of high sequence conservation (Figs. 9, 11, 13A, 13B, 13C, and 14). Conservation at a given sequence position is evaluated as the number of sequences bearing the most common residue divided by the total number of sequences. conserveed regions have a higher average conservation than the average for all sequence positions in the protein.
- Regional conservation is analyzed by an averaging window seven to fifteen (7-15) residues in length.
- Hydrophobic amino acids tend to participate in formation of a protein's hydrophobic core, which is a well-ordered portion of its three-dimensional structure. Hydrophilic segments are less well ordered and are preferred processing sites. Antigen segments involved in the core structure have higher hydrophobicity, as analyzed by an averaging window seven to fifteen (7-15) residues in length using the Kyte-Doolittle scale (Kyte and Doolittle, J. Mol. Biol. 157: 105-132, 1982). Epitopes are located between regions of low hydrophobicity or within regions of high hydrophobicity, defined relative to the average hydrophobicity for all residues in the protein (Figs. 10 and 12).
- NMR order parameters evaluated by measurement of NMR relaxation processes, define the degree of motion experienced by NMR-active nuclei on the time scale of picoseconds to nanoseconds. Regions of a protein that exhibit low order parameters are preferred processing sites, and regions of high order parameters contain epitopes.
- Some antibodies raised against protein antigens recognize both the antigen and a synthetic peptide corresponding to a sequence of the antigen. It is likely that these antibodies recognize the same sequence in both molecules. If these antibodies react with the antigen in the native state, the sequence must be exposed; whereas if the antibody reacts only with the denatured antigen, the sequence must be sequestered. Exposed sequences are preferred processing sites, and sequestered sequences contain epitopes.
- Proteolytic nick sites can be defined for an antigen by peptide mapping (isolation of the proteolytic products followed by sequencing). Proteolytic nick sites are preferred processing sites, and sequences between nick sites contain epitopes. VI. Additional Criteria Additional circumstances, such as the particular cell type or the presence of inflammation, may modify the spectrum of peptides generated. For example, local protease sensitivity may be significantly affected by the presence of components that bind to the antigen, such as antibodies or molecular chaperones. Indeed, antigen presentation was found to differentially affected for complexes of antigen with various monoclonal antibodies (Manca et al, J. Immunol. 9: 2893-2898, 1988).
- B-cell receptors might inhibit B-cell antigen processing by blocking the preferred processing sites, or conversely, enhance processing by locally destabilizing the structure.
- Investigators studying mouse models of autoimmune diseases, experimental allergic encephalomyelitis (Lehmann et al, Nature 358: 155- 157, 1992) and insulin-dependent diabetes (Kaufman et al, Nature 366: 69-72, 1993) have observed changes in the pattern of immunodominance over time after the initial immunization, a phenomenon known as "epitope spreading.” Migration of the dominant epitopes is thought to arise from successive rounds of antigen processing and presentation by evolving B cell populations (Mamula, M. J., Immunol. Rev.
- the present invention allows the generation of improved vaccines by insertion of unstable polypeptide segments into an antigen (e.g., HIV gpl20).
- the inserted segments are designed to enhance proteolytic processing at the site of insertion, resulting in enhanced presentation of epitopes from the antigen. Since presentation seems to be biased toward presentation of the sequence on the C-terminal side of an unstable segment, the insertion may be used to target presentation of a specific antigen sequence, such as one that is highly conserved and thus more likely to be broadly protective against pathogenic variants.
- Unstable polypeptide segments are expected to be preferred sites of proteolytic attack during antigen processing into peptides that will be presented in class II MHC antigen presenting proteins (and possibly also in class I antigen presenting proteins).
- the engineered polypeptide insert should not be shorter than twelve (12) residues or approximately the size of a protease recognition site; the insert should be composed of no more than 30% hydrophobic amino acids (He, Leu, Val, Tyr, Phe, T ⁇ , Thr, Met); the insert may contain a sequence recognized by a particular protease (e.g., a sequence recognized by the HIV protease); and the insert should not be predicted to form an ordered structure.
- the enhancement of epitope immunogenicity by insertion of unstable segments is expected to be most effective for the priming of CD4 helper T cells by antigen presenting cells, with presentation restricted by class II MHC proteins. This is the typical mode of presentation of "exogenous" antigens, e.g., subunit vaccines and proteins of bacteria, cell debris, and killed viruses. However, exogenous antigens can be presented in class I MHC proteins, and immunodominant helper T-cell epitopes often coincide with immunodominant cytolytic (CD8 + ) T-cell epitopes. Thus, enhancement of processing by insertion of unstable segments is a strategy to enhance cytolytic T cell responses to the targeted epitope. Identification of an Immunodominant Epitope in an Antigen
- Unstable polypeptide segments mark sites of enhanced proteolytic processing.
- the protein with the most poorly ordered polypeptide segment will be the most immunogenic.
- the most immunogenic antigen may be the most suitable for development as a subunit vaccine.
- the most immunogenic protein may contribute to autoimmune dysfunction and symptomology; and thus the epitope would be a candidate for development in a tolerogenic formulation. Stimulation of T cell proliferation indicates that a previous infection, immunization, or autoimmune process primed a response to the targeted epitope.
- Proliferation in response to an epitope of a pathogen protein by T cells from an infected individual indicates that the T cells were primed by the natural antigen. Observation of the proliferative response can provide useful information: The proliferative response to the epitope of a pathogen protein confirms that the T cell donor was exposed to the antigen and thus may have been or currently is infected with the corresponding pathogen.
- the response to the epitope of a pathogen protein indicates that the epitope is a candidate for immune enhancement in an engineered vaccine.
- a response to the epitope by T cells from an individual immunized with a pathogen protein or inactivated pathogen indicates priming against the epitope; and thus the epitope is a candidate for enhancement in an engineered vaccine.
- a response to an epitope from a self antigen indicates priming of an autoimmune response.
- An autoimmune response may be diagnostic of an autoimmune disorder, and the response to the epitope is the basis for design of a tolerogenic treatment with a formulation of the epitope.
- the most immunodominant epitopes of the HIV antigen, gpl20 have been predicted (see Fig. 6, black boxes).
- the CD4 + T lymphocytes of an individual who either is, or is suspected to be, infected with HIV may be isolated and used in a proliferation assay to determine responsiveness to the epitope presented on autologous antigen presenting cells.
- the presence of T lymphocytes which respond to the immunodominant epitope indicates that individual is infected with HIV. Furthermore, this information allows the assessment of the type of response the HIV infected individual is likely to generate against the virus.
- HIV gpl20 responsive CD4 + T lymphocytes may be assessed for an ability to stimulate either a cytotoxic T cell-mediated or antibody-mediated immune response through differential cytokine release. Knowledge of infection and type of response generated is useful for the treatment of infection with HIV, and other pathogens.
- T cell Epitope Alone or within an Engineered Recombinant Protein
- a variety of methods may be employed to produce the epitope, or epitope-containing antigen. For example, DNA sequences encoding the T cell epitope, or the epitope-containing antigen are introduced into a plasmid or other vector which is then used to transform living cells. Constructs in which the epitope, or epitope-containing antigen DNAs containing the entire open reading frames inserted in the correct orientation into an expression plasmid may be used for protein expression.
- Typical expression vectors contain promoters that direct the synthesis of large amounts of mRNA corresponding to the inserted epitope, or epitope-containing antigen nucleic acid in the plasmid bearing cells. They may also include eukaryotic or prokaryotic origin of replication sequences allowing for their autonomous replication within the host organism, sequences that encode genetic traits that allow vector-containing cells to be selected for in the presence of otherwise toxic drugs, and sequences that increase the efficiency with which the synthesized mRNA is translated. Stable long-term vectors may be maintained as freely replicating entities by using regulatory elements of, for example, viruses (e.g., the OriP sequences from the Epstein Barr Virus genome). Cell lines may also be produced which have integrated the vector into the genomic DNA, and in this manner the gene product is produced on a continuous basis.
- viruses e.g., the OriP sequences from the Epstein Barr Virus genome
- Expression of foreign sequences in bacteria requires the insertion of the T cell epitope, or epitope-containing antigen nucleic acid sequence into a bacterial or eukaryotic expression vector.
- This plasmid vector contains several elements required for the propagation of the plasmid in bacteria or eukaryotic cells, and expression of inserted DNA of the plasmid by the plasmid-carrying bacteria or eukaryotic cell. Propagation of only plasmid-bearing bacteria is achieved by introducing in the plasmid selectable marker-encoding sequences that allow plasmid- bearing bacteria to grow in the presence of otherwise toxic drugs.
- the plasmid also bears a transcriptional promoter capable of producing large amounts of mRNA from the cloned gene. Such promoters may or may not be inducible promoters which initiate transcription upon induction.
- the plasmid also preferably contains a polylinker to simplify insertion of the gene in the correct orientation within the vector.
- the expression vector plasmid contains a fragment of the E. coli chromosome containing the lac promoter and the neighboring lacZ gene.
- RNA polymerase normally transcribes the lacZ gene producing lacZ mRNA which is translated into the encoded protein, ⁇ -galactosidase.
- the lacZ gene can be cut out of the expression vector with restriction endonucleases and replaced by a T cell epitope, or epitope-containing antigen DNA sequence.
- this resulting plasmid is transfected into E. coli, addition of IPTG and subsequent transcription from the lac promoter produces epitope, or epitope-containing antigen mRNA, which is translated into epitope, or epitope-containing antigen polypeptides.
- the appropriate expression vectors containing a epitope, or epitope- containing antigen DNA are constructed, they are introduced into an appropriate host cell by transformation techniques including calcium phosphate transfection, DEAE- dextran transfection, electroporation, micro-injection, protoplast fusion and liposome-mediated transfection.
- the host cell which are transfected with the vectors of this invention may be selected from the group consisting of E. coli, pseudomonas, Bacillus subtilus, or other bacilli, other bacteria, yeast, fungi, insect (using, for example, baculoviral vectors for expression), mouse or other animal or human tissue cells.
- Mammalian cells can also be used to express the epitope, or epitope-containing antigen using a vaccinia virus expression system described in Ausubel et al. (Current Protocols in Molecular Biology. John Wiley & Sons, New York, NY, 1994).
- T7 late-promoter expression system In vitro expression of epitope, or epitope-containing antigen encoded by cloned DNA is also possible using the T7 late-promoter expression system.
- This system depends on the regulated expression of T7 RNA polymerase which is an enzyme encoded in the DNA of bacteriophage T7.
- the T7 RNA polymerase transcribes DNA beginning within a specific 23 -bp promoter sequence called the T7 late promoter. Copies of the T7 late promoter are located at several sites on the T7 genome, but none is present in E. coli chromosomal DNA.
- T7 RNA polymerase catalyzes transcription of viral genes but not of E. coli genes.
- E. coli cells are first engineered to carry the gene encoding T7 RNA polymerase next to the lac promoter. In the presence of IPTG, these cells transcribe the T7 polymerase gene at a high rate and synthesize abundant amounts of T7 RNA polymerase. These cells are then transformed with plasmid vectors that carry a copy of the T7 late promoter protein. When IPTG is added to the culture medium containing these transformed E. coli cells, large amounts of T7 RNA polymerase are produced. The polymerase then binds to the T7 late promoter on the plasmid expression vectors, catalyzing transcription of the inserted cDNA at a high rate. Since each E.
- E. coli contains many copies of the expression vector, large amounts of mRNA corresponding to the cloned cDNA can be produced in this system and the resulting protein can be radioactively labelled.
- Plasmid vectors containing late promoters and the corresponding RNA polymerases from related bacteriophages such as T3, T5, and SP6 may also be used for in vitro production of proteins from cloned DNA.
- E. coli can also be used for expression by infection with Ml 3 Phage mGPI-2.
- E. coli vectors can also be used with phage lambda regulatory sequences, by fusion protein vectors, by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.
- Eukaryotic expression systems permit appropriate post-translational modifications to expressed proteins.
- Transient transfection of a eukaryotic expression plasmid allows the transient production of an epitope, or epitope-containing antigen by a transfected host cell.
- a T cell epitope, or epitope-containing antigen may also be produced by a stably-transfected mammalian cell line.
- a number of vectors suitable for stable transfection of mammalian cells are available to the public (e.g., see Pouwels et al, Cloning Vectors: A Laboratory Manual. 1985, Supp. 1987), as are methods for constructing such cell lines (see e.g., Ausubel et al, supra).
- cDNA encoding an epitope, or epitope-containing antigen is cloned into an expression vector that includes the dihydrofolate reductase (DHFR) gene.
- Integration of the plasmid and, therefore, integration of the T cell epitope, or epitope-containing antigen-encoding DNA into the host cell chromosome is selected for by inclusion of 0.01-300 ⁇ M methotrexate in the cell culture medium (as described, Ausubel et al, supra). This dominant selection can be accomplished in most cell types.
- Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al.
- DHFR-containing expression vectors are pCVSEII-DHFR and pAdD26SV(A) (described in Ausubel et al, supra).
- the host cells described above or, preferably, a DHFR-deficient CHO cell line are among those most preferred for DHFR selection of a stably-transfected cell line or DHFR-mediated gene amplification.
- baculovirus system Another preferred eukaryotic expression system is the baculovirus system.
- One baculovirus expression system that is commercially available is the cloning vector pBacPAK9, which is available from Clontech (Palo Alto, CA). If desired, this system may be used in conjunction with other protein expression techniques, for example, the myc tag approach described by Evan et al. (Mol. Cell Biol. 5:3610-3616, 1985).
- the recombinant protein can be isolated from the expressing cells by cell lysis followed by protein purification techniques, such as affinity chromatography. Once isolated, the recombinant protein can, if desired, be purified further by e.g., by high performance liquid chromatography (HPLC; e.g., see Fisher, Laboratory Techniques In Biochemistry And Molecular Biology. Work and Burdon, Eds., Elsevier, 1980).
- HPLC high performance liquid chromatography
- Polypeptides of the invention can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis. 2nd ed., 1984, The Pierce Chemical Co., Rockford, IL). These general techniques of polypeptide expression and purification can also be used to produce and isolate immunodominant T cell epitopes for as described herein. Those skilled in the art of molecular biology will understand that a wide variety of expression systems may be used to produce the recombinant T cell epitope, or epitope-containing antigen. The precise host cell used is not critical to the invention.
- the epitope, or epitope-containing antigen may be produced in a prokaryotic host (e.g., E. coli) or in a eukaryotic host (e.g., S. cerevisiae, insect cells such as Sf9 cells, or mammalian cells such as COS-1. NIH 3T3, or HeLa cells). These cells are commercially available from, for example, the American Type Culture Collection, Rockville, MD (see also Ausubel et al, supra).
- the method of transformation and the choice of expression vehicle (e.g., expression vector) will depend on the host system selected. Transformation and transfection methods are described, e.g., in Ausubel et al. (supra), and expression vehicles may be chosen from those provided, e.g., in Pouwels et al, supra.
- HIV gpl20 is modified in an effort to create an anti- HIV vaccine, and the modified rgpl20 is administered with an adjuvant (ISCOM) intramuscularly.
- ISCOM adjuvant
- any adjuvant may be used, and the rgpl20, or any other T cell epitope derived from an antigen, or an antigen engineered to have enhanced T cell epitopes according to the methods described herein, may be administered without an adjuvant if so desired.
- more than one epitope may be administered simultaneously. For example, if there are two immunodominant epitopes of an antigen, or more than one antigen, both epitopes may be administered in concert.
- a T cell epitope derived from an antigen, or an antigen engineered to have enhanced T cell epitopes may be administered within any pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Methods of administration may differ depending upon whether the T cell epitope is being used as a vaccine, an immunostimulant for an already infected individual, or as a tolerogen for an individual suffering from an autoimmune disease.
- T cell epitopes derived from an antigen, or antigens engineered to have enhanced T cell epitopes may be employed to provide suitable formulations or compositions to administer T cell epitopes derived from an antigen, or antigens engineered to have enhanced T cell epitopes to patients suffering from a disease (e.g., virally-induced hepatitis) that is caused by an insufficient immune response, or to healthy individuals as a vaccine to prevent onset of a disease caused by an insufficient immune response.
- Administration may begin before an infected patient is symptomatic.
- administration may be parenteral, intravenous, intra-arterial, subcutaneous, intramuscular, intracranial, intravaginal, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, by suppositories, or oral administration.
- Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.
- Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes.
- Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
- T cell epitopes derived from an antigen, or antigens engineered to have enhanced T cell epitopes include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
- Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
- treatment with a T cell epitope derived from an antigen, or an antigen engineered to have enhanced T cell epitopes may be combined with more traditional therapies for the specific disease, such as surgery, steroid therapy, or chemotherapy for autoimmune disease; antiviral therapy for AIDS or other viral infections; and radiotherapy, chemotherapy, or surgery for cancer.
- HIV gp!20 A model case for enhanced immunogenic T cell epitopes
- a model case utilizing my T cell epitope detecting methods and application of these methods for the production of improved T cell epitopes by inserting unstable polypeptide segments into an antigen
- Gpl20 is produced by HIV, the etiological agent of Acquired Immunodeficiency Syndrome (AIDS).
- AIDS Acquired Immunodeficiency Syndrome
- a vaccine that confers protection against HIV infection may be developed. It will be clearly understood that although the following experiments pertain to HIV gpl20, the methods of the present invention may be used to manipulate any number of antigens from any number of sources, be they viral, bacterial, or eukaryotic in origin.
- CD4 + T lymphocytes In a normal immune response to a virus, CD4 + T lymphocytes typically activate cytotoxic CD8 + T lymphocytes, which then selectively kill virus-infected cells. Unfortunately, very little is known about what constitutes an effective CD4 + T lymphocyte response against HIV. Very few individuals mount protective immune responses against HIV following infection: most HIV infected patients eventually develop the fatal disease AIDS.
- the invention described herein will allow the augmentation of the CD4 + T cell response against HIV gpl20 through the engineering of enhanced T cell epitopes within gpl20. This will allow the development and use of vaccines which will stimulate an anti-HIV CD4 + T cell response, even in individuals already infected.
- the mobile loop of human Hsp 10 is ideally suited for use as a proteolytically sensitive insert that directs presentation of a flanking epitope in gpl20.
- the mobile loop of the M. leprae Hsp 10 (M. leprae cpnlO; see Fig 1 A) is associated with a C-terminal immunodominant T-cell epitope, and its immunodominance is likely to derive from enhanced proteolytic sensitivity in the adjacent loop.
- I have previously demonstrated enhanced sensitivity in mobile loops of two Hsp 10 proteins (Landry et al, Nature 364: 255-258, 1993; Landry et al, Proc. Natl. Acad. Sci. USA 93: 11622- 11627, 1996).
- Proteolytic sensitivity may be attributed to the loop's flexible disorder, and this is a conserved feature of all Hsp 10s so far examined. Insertion of a mobile loop should not significantly disturb the three-dimensional structure of gpl20. Loop disorder in the native Hsp 10 indicates a lack of conformational restraint within the loop, and thus it is not likely to distort flanking sequences. Since the ends of the loop lie close together in Hsp 10, insertion of the loop into gpl20 should mimic its native disposition, and therefore its native conformational flexibility should be preserved. The human HsplO mobile loop was selected over loops from other Hsp 10s because it is likely to be poorly immunogenic.
- the sites for loop insertion in gpl20 were chosen with the goal of enhancing the T-cell response to epitopes in gpl20 that are likely to be recalled upon HIV infection.
- the loop insertions also should not severely disturb potentially neutralizing antibody epitopes in gpl20.
- Sites in gpl20 were selected for insertion of flexible loops by the following preferred criteria: 1.
- the site should lie on the N-terminal side of a sequence that has characteristics of a good T-cell epitope: i) the sequence should be conserved among HIV variants; ii) the sequence should contain hydrophobic residues that will serve as anchors for binding in the MHC cleft; and iii) the sequence must not contain cysteines. A disulfide bond could restrict the availability of the target epitopes.
- the target T-cell epitope should be among epitopes primed in HIV infections.
- the site should not be located in a known neutralizing antibody epitope nor in a sequence where mutations are known to disturb a neutralizing antibody epitope.
- Each site is in a different conserved region of gpl20, and each lies within or N-terminal to an immunodominant region of gpl20 as defined by cellular proliferative responses. The predicted structural context and the potential damage to neutralizing antibody epitopes was also considered.
- Each insertion site is in a sequence predicted to form a turn or make a structural transition (Fig. 15). This will allow the loop to be exposed while causing the least disturbance to the gpl20 structure.
- Residue 81 lies in the Cl region immediately after a proline-rich sequence.
- Residue 334 lies just C-terminal to one of the cysteines that closes the V3 loop, in a segment of the C3 region for which no antibody specificity has been assigned and thus is likely to be buried. This site lies in the middle of an immunodominant region spanning the V3 loop and part of the C3 domain.
- Residue 468 lies in a glycine-rich sequence of the V5 domain, in a marginally solvent accessible segment N-terminal to a sequence rich in T-cell epitopes.
- the gpl20 proteins are expressed in insect cells using the baculovirus expression system and purified by lectin affinity chromatography. Furthermore, since envelope glycoproteins expressed in mammalian cells are better immunogens with respect to eliciting antibodies against conformational epitopes, development of stably transfected cell lines expressing rgpl20 proteins may also be employed. Transfection of plasmid DNA encoding rgpl20 proteins into a mammalian cell may be by any of the various methods (e.g., DEAE-dextran, CaP0 4 precipitation, electroporation) well known in the art of molecular biology (see Ausubel et al, supra).
- Mammalian cells stably inco ⁇ orating this exogenous DNA may be generated by co -trans fecting the rgpl20 protein- encoding DNA with DNA capable of expressing a eukaryotic selectable marker (e.g., the neo gene). Stable cell lines may then be generated by limiting dilution of G418- resistant transfected cell. Recombinant gpl20 proteins expressed by eukaryotic cells may also be purified by lectin affinity chromatography.
- a eukaryotic selectable marker e.g., the neo gene
- the rgpl20 proteins are expressed by baculovirus in insect cells and purified by lectin affinity chromatography.
- Recombinant baculovirus expressing the HIV- 1/89.6 gpl20 is prepared by recombination of baculovirus DNA with a transfer vector containing the HIV-1/89.6 gpl20 sequence, according to standard methods (see Ausubel et al, supra).
- the transfer vector will be prepared by replacing the gpl20 sequence in the HXBc2 transfer clone (Lu et al, J. AIDS Hum. Retrovir. 12: 99-106, 1996).
- rgpl20 proteins will be carried out in Hi-Five cells (commercially available from Invitrogen, Carlsbad, CA). The rgpl20 will be adsorbed to immobilized Galanthus nivalis agglutinin and eluted with methyl-alpha-D-mannopyranoside, as previously described (Gilljam, G., AIDS Res. And Hum. Retrovir. 9: 431-438, 1993). Using this method, 2 mg of protein per liter of culture is obtained.
- a sequence encoding the human cpnlO mobile loop is inserted into the gpl20 transfer vector after modification (e.g., by PCR amplification) to introduce unique restriction sites at the positions indicated above (see arrows in Fig. 15).
- the mobile loop sequence is amplified from the HsplO cDNA using primers containing restriction sites compatible with those engineered in the gpl20 sequence. It will be understood that processing site insertions may be inco ⁇ orated into more native-like immunogens. Likewise, this strategy for the enhancement of CD4 + T cell epitopes may be useful in other vaccine formulations, including DNA and virus-based immunogens.
- ISCOMs immunological complexes
- These protein micelles are added to the ISCOM formulation mixture consisting of 10 mg of cholesterol and 10 mg of phosphatidyl choline in 20% MEGA-10, followed by addition of 10 mg of the purified Quillaja saponin, QH-C (commercially availalbe from Isotec AB, Inc.). Following sonication, the mixture is left at 25°C for 60 min and then is dialyzed versus PBS overnight. The dialyzed sample is then centrifuged (200,000 x g) on a 20% sucrose cushion to pellet the rgpl20 containing ISCOMs. The amount of rgpl20 inco ⁇ orated into each adjuvant preparation is determined by visual inspection of SDS-PAGE resolved proteins.
- Group 1 200 ⁇ g of keyhole limpet hemocyanin formulated in ISCOMs.
- Group 2 200 ⁇ g of native, recombinant g ⁇ l20 formulated in ISCOMs.
- Group 3 200 ⁇ g of gpl20 containing a flexible insert at position 80 (rgpl20i80) formulated in ISCOMs.
- Group 4 200 ⁇ g of gpl20 containing a flexible insert at position 335 (rgpl20i335) formulated in ISCOMs.
- Group 5 200 ⁇ g of gpl20 containing a flexible insert at position 469
- ELISA to detect antibody against rgpl20 and peptides derived from gpl20
- Antibody titers against rgpl20 proteins and peptides thereof are determined as previously described (Pascual and Bost, Peptide Res. 2: 207-212, 1989; Pascual and Bost, Immunol. Invest. 19: 421-433, 1990; Takahashi et al, Inf. and Imm. 64: 12990- 1298, 1996; Takahashi et al, J. Infect. Dis. 173: 627-635, 1996). Briefly, microtiter plates are coated with rgpl20 protein, followed by blocking the plates with BSA.
- Sera is diluted in PBS containing 1% BSA to determine antibody titers. Serial 1 :3 dilutions beginning with a 1 :1000 dilution are used, and bound antibody detected using an HRP conjugated anti-human IgG ( ⁇ chain, Southern Biotechnology), followed by addition of substrate (TMB).
- HRP conjugated anti-human IgG ⁇ chain, Southern Biotechnology
- peptide mapping studies 48 peptides representing 20mers with overlapping 10 amino acid segments, derived from rgpl20 (strain 89.6), will be used. Two different dilutions of each sera (1 :25 and 1 :250) will be used to assure that reactivities can be accurately compared.
- CD4 + T lymphocyte response is performed.
- Phase 1 The CD4 + T lymphocyte response in each immunized primate using overlapping, synthetic peptides derived from HIV gpl20 strain 89.6. Since 48 overlapping 20 amino acid peptides are required to completely map gpl20, peptide pools are used initially to stimulate isolated CD4 + T lymphocytes. Autologous B lymphoblastoid cell lines (BLCL) are used to present the peptides. In addition, both TH1 (IL-2 and IFN- ⁇ ) and TH2 (IL-4 and IL-10) cytokine mRNA expression levels are determined. Establishment ofB lymphoblastoid cell lines (BLCL) for use as antigen presenting cells
- RhEBV Rhesus Epstein-Barr virus
- BLCL autologous B lymphocytic cell lines
- BLCL autologous B lymphoblastoid cell lines
- Peripheral blood mononuclear cells are isolated from 15 ml of Rhesus blood by centrifugation on hypaque-ficoll gradients.
- CD4 + T lymphocytes are then negatively selected using a two step process.
- the mononuclear leukocytes are incubated for 30 minutes at 4°C on polyclonal anti-human IgM (heavy and light chain, Southern Biotechnology Associates, Birmingham, AL) coated plates. This incubation not only specifically removes B lymphocytes, but also results in the removal of monocytes via non-specific adherence to the plastic plates.
- Mononuclear cells not adhering the anti-Ig coated plates are harvested, centrifuged and resuspended in media containing magnetic anti-CD8 conjugated microbeads (commercially available from Miltenyi Biotec, Auburn, CA). These magnetic beads are conjugated with the monoclonal anti-CD8 antibody (Leu 2A) which recognizes Rhesus CD8 (commercially available from Becton Dickinson). After 30 minutes, mononuclear cells not adhering to the anti-CD8 magnetic beads are removed, centrifuged, and counted. 10 6 CD4 + T lymphocytes per well are then added to the 24 well plates which already contain fixed, autologous BLCL and peptide antigen.
- RNA is isolated from each well to determine lymphokine mRNA profiles using semi-quantitative RT-PCR (see below).
- 100 ⁇ l of supernatant is taken at days 4 and 6 post stimulation for quantification by ELISA (also below).
- Phase 2 The antigen-specific TH1 and TH2 mRNA responses of CD4 + T lymphocytes from immunized Rhesus macaques are more accurately and quantitatively using the peptides defined in Phase 1. Specifically, for those pools of peptides which augment the TH1 or TH2 responses, a determination of which peptides in each pool were recognized is determined. Once again the readout will be RT-PCR for TH1 and TH2 lymphokine mRNA expression.
- Phase 3 Increased mRNA expression observed in Phase 2 translates into secretion of these lymphokines.
- ELISAs to quantify secretion of that particular lymphokine are performed.
- CD4 + T cell responses in HIV infection a focus on THl/TH2-derived cytokines There are at least two different functional subsets of CD4 + helper T lymphocytes
- TH which can be identified based on their ability to secrete particular lymphokines.
- Antigen-specific TH1 lymphocytes secrete substantial amounts of interleukin-2 (IL-2) and interferon- ⁇ (IFN- ⁇ ), and augment cell-mediated immune responses (e.g., cytotoxic T lymphocyte activity and macrophage activation).
- IL-2 interleukin-2
- IFN- ⁇ interferon- ⁇
- antigen-specific TH2 lymphocytes secrete IL-4, IL-5, IL-6, IL-10, and IL-13, and augment antibody production by B lymphocytes.
- Cytokine production which favors development of TH1 responses also serves to limit development of TH2 responses, and vice versa.
- stimulation of one T helper cell subset and not the other results in the production of a particular set of cytokines which may define the resulting immune response.
- T cell epitopes can be found to be associated with a TH1 or a TH2 immune response, then the present invention, which allows one to rationally enhance TH1 and/or TH2 responses against HIV gpl20, provides a significant advantage for vaccine development in HIV infected patients, as well as in non-infected individuals.
- Analyses of the antigen-specific CD4+ T lymphocyte responses may be performed, in this example, in three phases: Phase 1 : Twelve different pools of 4 consecutive, overlapping peptides derived from gpl20 are used to stimulate CD4 + T cells from each monkey previously administered gpl20 and variants thereof. mRNA lymphokine profiles will be performed on these cells.
- RNA extracted from antigen-stimulated CD4 + T lymphocytes is reverse transcribed using random hexamers as previously described (Bost, K. L., J. Neuroimmunol. 62L 59-67, 1995; Bost and Clements, Inf. and Imm. 63: 1076-1083, 1995; Bost and Mason, J. Immunol. 155: 285-296, 1995; Bost et al, J. Immunol. 154: 718-729, 1995; Bost et al, Immunol. 87: 633-641, 1996).
- RT-PCR Semi-quantitative RT-PCR is performed on each RNA sample for expression of TH1 (IL-2 and IFN- ⁇ ) and TH2 (IL-4, and IL-10) mRNAs using PCR primers specific for these respective cytokines.
- RT-PCR for the housekeeping gene, G3PDH is also performed on each sample to control for RNA loading.
- Phase 2 For those pools of peptides which stimulate the most significant differences in cytokine mRNA expression between native gpl20 immunized primates and those immunized with rgpl20 containing flexible segments, a second set of antigen-stimulations is performed. Here the individual peptides making up the peptide pool are used to obtain a more accurate map of peptide-stimulated lymphokine mRNA expression, as described herein. Focus is on the peptide pools which result in the most significant differences in stimulating CD4 + T lymphocyte mRNA expression in animals immunized with native rgpl20 versus the other three groups immunized with rgpl20 containing flexible regions.
- peptide pool #2 did not stimulate significant cytokine mRNA expression in CD4 + lymphocytes of primates immunized with native ⁇ gl20, but primates immunized with rgpl20i80 did respond to peptide pool #2, such a difference would be a primary focus of my investigations.
- Phase 3 For those peptides which stimulate significant increases in TH1 or TH2 lymphokine mRNA expression, secretion of these lymphokines is then quantified using ELISAs as follows:
- IL-2 ELISA A monoclonal anti-human IL-2 antibody (MQ1-17H12; commercially available from Pharmingen, San Diego, CA) is used as a capture antibody and a biotinylated, polyclonal anti-human IL-2 antibody (Pharmingen) will be used as a detection antibody, and the ELISA assay conducted according to standard methodologies (Ausubel et al, supra). Both of the anti-human IL-2 reagents cross react with Rhesus IL-2 (Pharmingen Technical data sheet).
- IL-4 ELISA A commercially available anti-human IL-4 capture ELISA
- IL-10 ELISA A commercially available anti-human IL-10 capture ELISA (R&D Systems, Minneapolis, MN) which crossreacts with Rhesus IL-10, and does not recognize Epstein Barr-produced viral IL-10 (R&D Systems technical services report) will be used.
- IFN- ⁇ ELISA A commercially available anti-human IFN- ⁇ ELISA (Genzyme, Cambridge, MA) which crossreacts with Rhesus IFN- ⁇ (Genzyme technical bulletin) will be used.
- the anti-IL-2 antibody pair was tested on culture supernatants from mitogen stimulated, Rhesus peripheral blood mononuclear cells. There was significant crossreactivity, confirming the findings of the Pharmingen technical support staff.
- Rhesus IL-2, IL-10 and IFN- ⁇ will be cloned, expressed, and purified using the pFLAG expression system as previously described (Bost et al, Immunol. 87: 633- 641, 1996).
- peptide pools #1, 3, 5, etc. do not stimulate significant cytokine mRNA expression in any of the immunized animals. Hence, there is no need to further map these regions of gpl20 or to use these peptides to stimulate lymphokine secretion.
- phase 2 and phase 3 investigations will focus on differences in antigen-specific CD4 + lymphokine expression between those animals immunized with native rgpl20 versus those immunized with the rgpl20 proteins containing flexible regions (i.e., rgpl20i80, rgpl20i335, and rgpl20i469).
- Vaccines targeting HIV gpl20 the ability of a subunit HIV gp!20 vaccines to stimulate humoral and CTL responses
- a subunit vaccine like HIV gpl20 may be used to stimulate humoral or CTL responses.
- the type of immune response against this subunit vaccine candidate which ultimately dominates can depend upon a variety of factors (reviewed in Haynes, B. F., Lancet 348: 933-937, 1996; McElrath et al, AIDS Res. Hum. Retrovir. 13: 211-216, 1997).
- the present invention allows an exploration into the possibility that by enhancing presentation of HIV g ⁇ l20 peptides to CD4 + T cells epitopes, it will be possible to augment the immune response since CD4 + T cell help is necessary for optimal humoral immunity and CTL responses.
- CEMxl74 cells (publically available from the NIH AIDS Research and Reference Reagent Program) are transfected with the ligation of p5'SHIV with p3'89.6u+SHIV, according to methods previously described (Li et al, J. Virol 69: 7061-7067,1992).
- Virus stocks are prepared by infecting Rhesus monkey peripheral blood mononuclear cells. Viral titers are determined from cell-free supernatants using serial dilutions of virus containing supernatants placed on CEMxl74 cells.
- the 50% tissue culture infectious dose (TCID50) is calculated from microscopic inspection of syncytia formation after 2 weeks. Antibody neutralization is performed essentially as described (Lu et al, J.
- serial dilutions (1 :3, beginning at a sera dilution of 1 :30) of heat inactivated sera from each Rhesus monkey is mixed with 200 TCID50 of SHIV at 37°C for 60 min. 10 5 CEMxl74 cells are then added to each well, and four days viral production is measured by quantifying SIV p27 antigen release into the culture supernatant (Coulter Co,. Miami, FL). Neutralizing titers are defined as the last dilution to provide 50% protection when compared SIV p27 levels in control antibody treated wells challenged with virus.
- CTL assays Cytotoxic T lymphocyte (CTL) responses are performed as previously described (Voss et al, Virol. 208: 770-775, 1995).
- Peripheral blood mononuclear cells are isolated and cultured for three days in RPMI 1640 containing 10% FCS and gentamicin with 2 ⁇ g/ml of concanavalin A. After three days, the cells are expanded into media containing 100 U/ml recombinant human IL-2 for an additional two days.
- BLCL autologous B lymphoblastoid cell lines established for each Rhesus monkey as described above are infected with the recombinant vaccinia virus, vBD3 (Dr.
- Augmented humoral antibody responses against selected epitopes within HIVgpl20 are found when comparing between groups of immunized macaques. Specifically, insertion of flexible regions into rgpl20 immunogens is found to augment and focus the CD4 + T cell response to particular epitopes, and this in turn focuses T cell help. The result of such manipulation is an augmentation and focusing of the humoral immune response.
- An augmented CTL response against selected epitopes of HIV gpl20 is also found when comparing between groups of immunized macaques. Specifically, insertion of flexible regions into rgpl20 immunogens augment and focus the CD4 + T cell response to particular epitopes, and this in turn focuses T cell help. The result of such manipulation is an augmentation and focusing of the CTL response as well.
- SHIVs Simian/human immunodeficiency viruses
- SIVs were developed specifically to overcome the shortcomings of SIV for HIV drug and vaccine development (Li et al, J. AIDS 5: 639-646, 1992).
- SHIVs combine the gag and pol genes of SIV with the env gene of HIV.
- a new SHIV encoding the envelope glycoprotein of the macrophage tropic HIV strain designated HIV-1/89.6 that is particularly cytopathic in human cells was recently developed (Reimann et al, J. Virol 70: 3198-3206, 1996; Reimann et al, J. Virol. 70: 6922-6928, 1996).
- the close similarity of SHIV-89.6 infection to rapidly progressing HIV infection coupled with the potential for testing anti-HIV envelope glyoprotein immune responses makes the SHIV-89.6 an exceptional model system for testing novel vaccines.
- Rhesus monkeys pre-immunized with rgpl20 are challenged with SHIV infection to assess resistance conferred by the rgpl20 immunization.
- non- immunized animals may also be infected with SHIV, followed by immunization with rgpl20 to assess the effects of the rgpl20 vaccine in ameliorating the symptoms of SHIV infection.
- helper T-cell epitopes on the basis of local antigen stability was next examined with a model antigen, bacteriophage T4 Gp31 (SEQ ID NO: 2; GenBank Accession No. M34502).
- This protein is homologous to the M. leprae GroES in terms of its three-dimensional structure and local stability, but the proteins share less than 20% sequence identity.
- the pattern of helper T-cell epitope immunodominance in Gp31 was determined by mapping lymphoproliferative responses with overlapping synthetic 15-mer peptides spanning the Gp31 sequence.
- mice Two groups of C57/B6 mice (commercially available from the Jackson Laboratory, Bar Harbor, ME) were immunized as follows:
- Group 1 100 ⁇ g Gp31 (full length protein) plus 100 ⁇ l Freund's complete adjuvant in a total volume of 200 ⁇ l (100 ⁇ l intrapertoneal and 100 ⁇ l subcutaneous).
- KLH keyhole limpet hemocyanin
- Freund's complete adjuvant in a total volume of 200 ⁇ l (100 ⁇ l intrapertoneal and 100 ⁇ l subcutaneous).
- mice At 10 and 21 days after immunization, all mice given a boost of 50 ⁇ g Gp31 (group 1) or KLH (group 2) with 50 ⁇ l Freund's incomplete adjuvant in a total volume of 100 ⁇ l intraperitoneally. At 22 days after the second boost, one mouse of each group was sacrificed, and total splenic cells were obtained. Cells (2xl0 5 ) were incubated for several days with 100 ⁇ g of each 15-mer peptide and then [ 3 H]thymidine was added to the cell culture media, according to standard methods (see, e.g., Ausubel et al, supra; Coligan, J.E., Current Protocols in Immunology. John Wiley & Sons, New York, NY, 1991).
- Fig. 16A The results shown in Fig. 16A are reported as a Stimulation Index (SI), which is defined as the ratio of background-subtracted radioactivity for cells primed with Gp31 to cells primed with the irrelevant antigen, KLH.
- SI Stimulation Index
- a predicted epitope is the basis for design of a tolerogenic epitope that reduces immune responses.
- the epitope is derived from a self antigen, such as insulin, diabetes, or a predisposition to develop diabetes, may be detected in a patient by using the methods of the present invention to isolate an immunodominant epitope of insulin.
- the patient's T lymphocytes may then be isolated and utilized in a T cell proliferation assay (e.g., 3 H-thymidine inco ⁇ oration assay) following stimulation with the epitope in the context of fixed autologous antigen presenting cells according to the methods described herein, and, additionally, following methods described in Ausubel et al, supra.
- Non-radioactive cell proliferation assays are also known in the art (e.g., the CellTiter 96® AQ ueous Non-Radioactive Cell Proliferation Assay commercially available (Promega Co, Madison, WI). Should the patient prove to have T cells which do respond to insulin, tolerogenic epitopes may be designed which may then be administered to the patient to tolerize insulin-specific T cells, thereby preventing onset of diabetes and/or alleviating diabetic symptoms. Design of Tolerogens for Treatment of Autoimmune or Allergy Disorders
- the dose of the administered antigen is an important variable. Very high concentrations of soluble proteins have been shown to be required to suppress the antibody response (Dixon and Maurer, J. Exp. Med. 101 : 245-257, 1955). It has also been shown that extremely low doses of antigen can also induce tolerance (Mitchison, N. A., Proc. Roy. Soc. Lond. (Biol.) 161 : 275-292, 1964).
- the route of antigen introduction is a critical factor in tolerance induction. Intravenous or oral administration of antigen generally favors induction of tolerance (Cremer et al, J. Immunol. 131: 2995-3000, 1983; Chase, M., Proc. Soc. Exp. Biol. 61 : 257-259, 1946).
- such epitopes are defined for the targeted auto-antigen of any number of autoimmune diseases including, without limitation, insulin (diabetes), acetylchohne receptor (Myasthenia gravis), synovial proteins (Rheumatoid arthritis), erythrocyte membrane proteins (autoimmune hemolytic anemia), type IV collagen (Goodpasture's syndrome), and thryoid- stimulating hormone receptor (Graves' disease).
- Peptide mapping of these auto- antigens may be undertaken to identify the immunodominant T cell epitope recognized by T lymphocytes of patients with autoimmune disease using the methods described herein.
- an immunodominant T cell epitope to an auto-antigen may be used to tolerize and/or remove reactive cells from a patient with the autoimmune disease, or with a predisposition to develop the disease.
- the epitope may also be used to screen individuals who have auto-reactive T cells, but who are, as yet, a-symptomatic.
- Antigen presenting cells may be generated according to the methods described herein from a patient being screened and/or treated for an autoimmune disease. It will be understood that such antigen-presenting cells may be expanded in vitro to attain large numbers of cells autologous to an individual patient. Following incubation of the antigen-presenting cell with the immunodominant T cell epitope of, for example, the thryoid-stimulating hormone receptor, the blood of a patient with Graves' disease may be collected and passaged over a surface covered antigen-presenting cells presenting the immunodominant T cell epitope of the thyroid-stimulating hormone receptor.
- T lymphocytes which recognize and bind to the T cell epitope presented on autologous antigen-presenting cells will adhere to the immobilized cell, thus exiting the blood.
- the thyroid-stimulating hormone receptor-specific T lymphocyte-depleted blood is then returned to the patient.
- T lymphocytes which recognize self-peptide in the context of self-MHC will be eliminated, hence preventing and/or alleviating Graves' disease symptoms.
- the blood of an autoimmune patients may be passaged over autologous antigen-presenting cells presenting the immunodominant T cell epitope of the targeted auto-antigen in bulk, in a method akin to dialysis treatment of diabetic patients.
- auto-antigen specific T lymphocytes may be depleted in one, albeit lengthy, treatment.
- T cells mediating allergic reactions to, for example, pollen may be similarly removed by incubating autologous antigen presenting cells with the immunodominant T cell epitope of a pollen antigen detected by the methods disclosed herein. By removing these pollen-reactive T cells from the allergic patient, allergy symptoms may be alleviated.
- a state of immunological unresponsiveness can be induced if a T cell is presented a peptide in context with autologous MHC, but without the additional presence of a number of costimulatory molecules on the antigen presenting cell which include, without limitation, B7 (CD80), ICAM-1 (CD54), LFA-3 (CD58), and CD72 (Mueller et al, Ann. Rev. Immunol. 7: 445-480, 1989).
- B7 CD80
- ICAM-1 CD54
- LFA-3 CD58
- CD72 Costimulatory molecules on the antigen presenting cell
- antigen presenting cells may be isolated from patients with Goodpasture's syndrome (also known as glomerulonephritis).
- the antigen presenting cells may be incubated with the collagen type IV immunodominant T cell epitope in addition to incubation with antibodies which bind to one or more of the costimulatory molecules on the antigen presenting cell.
- antibodies are widely commercially available.
- anti-human B7, ICAM-1, LFA-3, and CD72 antibodies are all available from Coulter Co. (Miami, FL).
- anti-B7 antibody may be used to ensure complete blocking of the B7 antigen on the antigen presenting cell.
- T cells from a Goodpasture's syndrome patient are then incubated with these costimulation molecule-blocked autologous antigen-presenting cells presenting the immunodominant type IV collagen T cell epitope.
- Such treatment will tolerize any type IV collagen reactive T cells in the sample. Repeated treatments will allow the complete anergy of all type IV collagen reactive T lymphocytes, thus alleviating and/or preventing Goodpasture's syndrome.
- tolerization treatments may be modified into one extended treatment, thereby passaging the entire blood supply of the patient over autologous costimulation molecule-blocked antigen cells presenting type IV collagen.
- T cells of patients suffering from allergies e.g., to pollen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU85952/98A AU8595298A (en) | 1997-07-29 | 1998-07-28 | Prediction, detection, and design of t cell epitopes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5415697P | 1997-07-29 | 1997-07-29 | |
US60/054,156 | 1997-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006061A1 true WO1999006061A1 (en) | 1999-02-11 |
Family
ID=21989113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015563 WO1999006061A1 (en) | 1997-07-29 | 1998-07-28 | Prediction, detection, and design of t cell epitopes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8595298A (en) |
WO (1) | WO1999006061A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004528013A (en) * | 2000-10-02 | 2004-09-16 | ジェネンコー・インターナショナル・インク | Proteins that produce altered immune responses and methods of making or using the same |
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US6936249B1 (en) * | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
CN103941018A (en) * | 2014-03-27 | 2014-07-23 | 金华职业技术学院 | Cell-B antigenic epitope screening and function identification method of main outer membrane protein OMP 18 of campylobacter jejuni |
-
1998
- 1998-07-28 WO PCT/US1998/015563 patent/WO1999006061A1/en active Application Filing
- 1998-07-28 AU AU85952/98A patent/AU8595298A/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
"HYPOTHESIS FOR THE CONTROL OF CLOTTING FACTOR VIII INHIBITORY ANTIBODIES BY DECREASING POTENCY OF HELPER T-CELL-RECOGNIZED EPITOPES IN FACTOR VIII", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 36, no. 05, 1 November 1992 (1992-11-01), GB, pages 653 - 660, XP002913590, ISSN: 0300-9475 * |
ABRAMS S I, ET AL.: "MUTANT RAS EPITOPES AS TARGETS FOR CANCER VACCINES", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, vol. 23, no. 01, 1 February 1996 (1996-02-01), US, pages 118 - 134, XP002913589, ISSN: 0093-7754 * |
MARTIN S., ET AL.: "SELECTIVE ACTIVATION OF CD8 T CELL EFFECTOR FUNCTIONS BY EPITOPE VARIANTS OF LYMPHOCYTIC CHORIOMENINGITIS VIRUS GLYCOPROTEIN.", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157., no. 06., 1 September 1996 (1996-09-01), US, pages 2358 - 2365., XP002913588, ISSN: 0022-1767 * |
MIKSZTA J. A., KIM B. S.: "CONVERSION OF LOW ANTIBODY RESPONDERS INTO HIGH RESPONDERS BY UP-REGULATING THE T CELL RESPONSE TO A SELECTIVE EPITOPE.", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157., no. 07., 1 October 1996 (1996-10-01), US, pages 2883 - 2890., XP002913587, ISSN: 0022-1767 * |
SCHULZ M., ET AL.: "MAJOR HISTOCOMPATIBILITY COMPLEX BINDING AND T CELL RECOGNITION OF A VIRAL NONAPEPTIDE CONTAINING A MINIMAL TETRAPEPTIDE.", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 21., no. 05., 1 May 1991 (1991-05-01), DE, pages 1181 - 1185., XP002913591, ISSN: 0014-2980, DOI: 10.1002/eji.1830210513 * |
TIEDAN SUN, ET AL.: "INTERLEUKIN-2-SECRETING MOUSE FIBROBLASTS TRANSFECTED WITH GENOMIC DNA FROM MURINE NEOPLASMS INDUCE TUMOR-SPECIFIC IMMUNE RESPONSES THAT PROLONG THE LIVES OF TUMOR-BEARING MICE", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 02, no. 03, 1 September 1995 (1995-09-01), GB, pages 183 - 190, XP002913592, ISSN: 0929-1903 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
US6936249B1 (en) * | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
JP2004528013A (en) * | 2000-10-02 | 2004-09-16 | ジェネンコー・インターナショナル・インク | Proteins that produce altered immune responses and methods of making or using the same |
CN103941018A (en) * | 2014-03-27 | 2014-07-23 | 金华职业技术学院 | Cell-B antigenic epitope screening and function identification method of main outer membrane protein OMP 18 of campylobacter jejuni |
Also Published As
Publication number | Publication date |
---|---|
AU8595298A (en) | 1999-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cormier et al. | Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A | |
US6265539B1 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
US10898567B2 (en) | Synthetic long peptides (SLP) for therapeutic vaccination against Hepatitis B virus infection | |
JP3491896B2 (en) | Immunomodulatory peptide | |
EP0271577B1 (en) | Immunomodulating compositions and their use | |
CA2027317A1 (en) | Vaccine composition with non-immunosuppressive t-cell epitope component | |
JP2002529112A (en) | HIV-specific T cell induction | |
MX2008010113A (en) | Peptide sequences and compositions. | |
EP0400076B1 (en) | A synthetic antigen evoking anti-hiv response | |
WO1994004557A1 (en) | Immunomodulatory peptides | |
EP0474764A1 (en) | Method to treat rheumatoid arthritis | |
WO2004031212A1 (en) | Antigenic peptides | |
EP2021356B1 (en) | Hiv vaccine | |
WO1999006061A1 (en) | Prediction, detection, and design of t cell epitopes | |
EP0601108B1 (en) | Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects | |
Shi et al. | Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice | |
CA2115424A1 (en) | Immunostimulation | |
EP2324049B1 (en) | Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine | |
Wu et al. | The Dermatophagoides pteronyssinus group 2 allergen contains a universally immunogenic T cell epitope | |
Sheil et al. | Identification of an autologous insulin B chain peptide as a target antigen for H-2Kb-restricted cytotoxic T lymphocytes. | |
Sundaram et al. | Protective Efficacy of Multiepitope Human Leukocyte Antigen–A* 0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia Virus | |
JP2010029217A (en) | Hiv-specific ctl inducing peptide and medicament for preventing or treating aids comprising the peptide | |
Mishra et al. | Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen. | |
JP2004242599A (en) | Cd8+ cytotoxic t-lymphocyte epitope peptide and application thereof | |
RU2539035C2 (en) | Preventive or therapeutic polyepitopic anti-tuberculosis vaccine construction providing induction of cellular immune response of cd4+ or cd8+ t-lymphocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999511078 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09463590 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |